About Amphera
Amphera is a company based in 's-hertogenbosch (Netherlands) founded in 2012. Amphera offers products and services including MesoPher. Amphera operates in a competitive market with competitors including TScan Therapeutics, GigaGen, Shattuck Labs, Boundless Bio and Bolt Biotherapeutics, among others.
- Headquarter 's-hertogenbosch, Netherlands
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Amphera B.V.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$52.13 K (USD), Grant
Jan 01, 2016
-
Investors
European Union
& 2 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Amphera
Amphera offers a comprehensive portfolio of products and services, including MesoPher.
Autologous dendritic cell therapy for treating mesothelioma and pancreatic cancer.
Funding Insights of Amphera
Investors in Amphera
Amphera has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union, RedMedTech Discovery Fund and Brabant Life Sciences Seed Fonds.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Funding is provided for innovations in medical technology startups.
|
Locked | Locked | Locked | |
|
Seed funding is offered for life sciences startups.
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for Amphera
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Amphera
Investment portfolio details for Amphera
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Amphera
Detailed financials for Amphera
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Amphera Comparisons
Peer comparison for Amphera
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Amphera
Amphera operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as TScan Therapeutics, GigaGen, Shattuck Labs, Boundless Bio and Bolt Biotherapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| Locked | Locked | Locked |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms.
|
|
| Locked | Locked | Locked |
An immunotherapy platform for oncology and other diseases is developed.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer are developed by targeting ecDNA.
|
|
| Locked | Locked | Locked |
T-cell therapies for cancer treatment are developed by Bolt Biotherapeutics.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
Detailed competitors of Amphera
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Amphera
Complete news archive for Amphera
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Amphera
Amphera was founded in 2012 and raised its 1st funding round 2 years after it was founded.
Amphera is headquartered in 's-hertogenbosch, Netherlands. It is registered at 's-hertogenbosch, Noord-brabant, Netherlands.
Rob Meijer is the current CEO of Amphera.
Amphera was founded in 2012 and is engaged in the biotechnology sector, where dendritic cell immunotherapies are developed for malignant mesothelioma and additional cancers. The lead candidate, MesoPher, is formulated using mesothelioma tumor cells instructed with a lysate. Operations focus on advancing these treatments through research and clinical development, with activities based in the Netherlands.
Amphera's top competitors include Lyell Immunopharma, GigaGen and Shattuck Labs.
Amphera offers MesoPher.
Amphera has 3 investors. Key investors include European Union, RedMedTech Discovery Fund, and Brabant Life Sciences Seed Fonds.